BioCentury
ARTICLE | Product Development

Contrarian thinking

Why Genentech, Roche say neuroscience R&D is ripe for investment

October 8, 2012 7:00 AM UTC

While many pharma companies are exiting or externalizing neurology R&D, a few have decided to double down, seeing the glimmer of a new understanding of CNS diseases where others see biological black boxes leading to late-stage clinical failures.

Among these contrarians, Roche and its Genentech Inc. unit say neuroscience is breaking open because of advances in genetics, imaging and an improved understanding of pathways and targets...